



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3592401>Available online at: <http://www.iajps.com>

Research Article

**A STUDY TO ASSESS BIOCHEMICAL AND
HAEMATOLOGICAL ABNORMALITIES OF DENGUE FEVER
PATIENTS IN TERTIARY CARE HOSPITAL**Dr. Tashfeen Mumtaz¹, Dr. Shoaib Ahmad¹, Dr. Sania Naseem²¹ Rawalpindi Medical University, Rawalpindi² Ayub Medical College, Abbottabad

Article Received: October 2019 Accepted: November 2019 Published: December 2019

Abstract:

Objective: The purpose of this study was to determine the pattern of clinical presentations, haematological and biochemical abnormalities and outcome of dengue fever patients.

Study Design: A descriptive cross-sectional study.

Place and Duration of Study: This study was conducted in Department of Medicine, Benazir Bhutto Hospital, Rawalpindi from August, 2018 to July, 2019.

Material and Methods: Patients meeting the inclusion criteria were admitted at Benazir Bhutto Hospital Rawalpindi and blood serology was done to confirm the diagnosis of dengue fever. Cases with positive dengue serology were included in the study. Clinical symptoms, signs, investigations and outcome of these patients were recorded on a proforma. Blood samples were taken for analysis. Chest X-Ray and ultrasound abdomen were done on required basis.

Results: Out of forty confirmed cases of dengue fever, there were 25 (62.5%) males and 15 (37.5%) females. Mean age was 40 years. There were 39 cases (97.5%) of dengue fever and one case (2.5%) of dengue shock syndrome. There was no case of dengue haemorrhagic syndrome. Maximum cases were seen in the month of September, 2018. The clinical features noted were: headache and myalgias 62.5%, chills and rigors 57.5%, retro-orbital pain 42.5%, vomiting 35.0%, pruritus 27%, skin rash 20%, abdominal pain 20%, diarrhoea 10%, bleeding 2.5%, ascites and pleural effusion 2.5%, and hepatomegaly 15%. The laboratory findings were: leucopenia 85% and thrombocytopenia 92.5%. Serum alanine transaminase (ALT), urea, and creatinine were raised in 30%, 2.5% and 7.5% cases respectively. Mortality was 2.5%.

Conclusion: This study showed that patients admitted to Benazir Bhutto hospital had a milder presentation of dengue fever in the year 2018-2019.

Keywords: Dengue fever, Leucopenia, Thrombocytopenia.

Corresponding author:**Dr. Tashfeen Mumtaz,**

Rawalpindi Medical University, Rawalpindi

QR code



Please cite this article in press Tashfeen Mumtaz et al., A Study To Assess Biochemical And Haematological Abnormalities Of Dengue Fever Patients In Tertiary Care Hospital., Indo Am. J. P. Sci, 2019; 06(12).

INTRODUCTION:

Dengue fever (DF) is a viral infection transmitted to the humans through the bites of infected *Aedes* mosquitoes which mainly breed on the surface of clean stagnant water. Once a patient is infected with dengue virus, the illness could range from minor symptoms to serious manifestations such as dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). However, in 20% cases, the infected person remains asymptomatic [1].

Dengue virus has four serotypes referred as DEN-1 to 4. Primary infection induces lifelong protective immunity to the infecting serotype, but results only in partial and transient protection against subsequent infection by other serotypes. Subsequent infection with another serotype can cause life threatening illness [2]. All four serotypes of dengue virus have been isolated in different epidemics in Pakistan. DEN1 and DEN2 were confirmed in 1998, DEN2 and DEN3 in 2006 outbreak at Karachi, and DEN-2 was the predominant serotype in 2011 epidemic at Lahore [3,4,5]. There is a firm evidence that patients with DEN-2 infections have a worse outcome than patients with other serotypes [6].

There is a sharp increase in the number of dengue fever cases in recent years with an alarming impact on both human health and the global and national economies. The actual numbers of dengue cases are underreported and often misclassified. A recent estimate indicates 390 million dengue infections per year [7]. In Pakistan, 48,188 laboratory confirmed cases were reported during 2011-2014 [8].

The toll that this disease is exacting on the economy and health makes it imperative to study it in greater depth. A review of the literature revealed that presentation of dengue fever had wide temporal and regional variations. Several studies were done in Lahore, south Punjab and in Sind. However only limited studies were carried out in Rawalpindi region.

MATERIAL AND METHODS:

This descriptive cross-sectional study with prospective data collection were carried out at Benazir Bhutto Hospital, Rawalpindi from August, 2018 to July, 2019. 40 patients were selected through non-probability purposive sampling technique. Inclusion criteria were: patients 12 years or older presenting with acute fever associated with two or more of the following; headache, retro-orbital pain, myalgias, arthralgia, rash,

abdominal pain, haemorrhagic manifestations, leucopenia, thrombocytopenia or circulatory collapse in whom tests for dengue fever, NS1 antigen or IgM serology or both were positive.



Patients having haematological diseases such as idiopathic thrombocytopenia (ITP), haematological malignancy, myeloproliferative disorder, myelodysplasia, bone marrow infiltrative disorder, immune disorder, and patients taking steroids or cancer chemotherapy were excluded from the study.

A detailed history was obtained and thorough physical examination was done in all patients who were included in the study. Blood samples were obtained for blood complete picture (CBC), haematocrit (Hct), liver function tests (LFTs), serum urea, serum creatinine, serum electrolytes, and prothrombin time (PT). NS1 antigen was done in all patients and IgM serology was done if duration of illness was more than 5 days. Further tests like chest X-Ray, ultrasound abdomen, International normalized ratio (INR), D dimers and partial thromboplastin time (PTT) were carried out if required. CBC and Hct were done daily till defervescence. A rise in Hct from baseline is considered one of the indicators of plasma leak in DSS 1. As we didn't have patients' baseline haematocrit, we arbitrarily took a value above 45% in males and 40% in females to be of significance and followed these cases for plasma leak. Leucopenia was defined as total white cell count less than $4000 \times 10^9/L$ and thrombocytopenia if platelet count was less than $150 \times 10^9/L$.

The dengue fever cases were further sub- classified in to DF, DHF and DSS according to World Health Organization (WHO) definition criteria of dengue infection [1]. Data were collected on a proforma, prepared based on already reported signs, symptoms and laboratory parameters in the literature. Statistical Analysis was performed by using SPSS version 20. Descriptive statistics were used to analyze the data. Mean and standard deviation were calculated for quantitative variables. Categorical variables were presented by frequency and percentage.

RESULTS:

Forty serologically confirmed cases of dengue were included in our study. There were 25 males (62.5%) and 15 females (37.5%) with a male to female ratio of 1.7:1. Patients' mean age was 40 ± 15.95 years (range 15 to 85 years). Figure shows the distribution of cases according to the month in which they presented.



There were 39 cases (97.5%) of DF while only one case (2.5%) met the criteria of DSS. There was no case of DHF. Patients were admitted to hospital after a mean 4 ± 1.7 days from onset of fever. Mean temperature during illness was $101.3 \pm 1.13^{\circ}\text{F}$ and duration of fever was 5.98 ± 1.51 days. Table-I presents clinical manifestations. None of the patient in the category of DF had bleeding manifestations, jaundice, lymphadenopathy, splenomegaly, pleural effusion or ascites; however, 5 of them had hepatomegaly. There was only 1 patient of DSS. He had epistaxis, haematuria, ecchymosis, bleeding from gums and lower gastrointestinal bleed. He also had hepatomegaly, bilateral pleural effusion and ascites.

Table No 01: Distribution of clinical manifestations of dengue fever (n=40)

<i>Symptoms/signs</i>	<i>No. of patients</i>	<i>Percentage %</i>
<i>Headache</i>	25	62.5
<i>Myalgias</i>	25	62.5
<i>Chills and rigors</i>	23	57.5
<i>Retro-orbital pain</i>	17	42.5
<i>Vomiting</i>	14	35.0
<i>Weakness/fatigue</i>	9	22.5
<i>Pruritus</i>	11	27.5
<i>Skin Rash</i>	8	20
<i>Joint pain</i>	7	17.5
<i>Diarrhoea</i>	4	10
<i>Bleeding</i>	1	2.5
<i>Abdominal pain</i>	8	20
<i>Hepatomegaly</i>	6	15
<i>Ascites</i>	1	2.5
<i>Pleural Effusion</i>	1	2.5
<i>Splenomegaly</i>	0	0
<i>Lymphadenopathy</i>	0	0

Table-II shows laboratory results. On admission the mean haemoglobin was 14.5 ± 1.45 grams/dl in males, and 12.8 ± 1.41 grams/dl in females, white cell count was $4.09 \pm 1.83 \times 10^9/L$ and mean platelet count was $115.9 \pm 44.9 \times 10^9/L$. Four male patients and 1 female patient were having Hct above 45% and 40% respectively. Out of these patients, only 1 male patient later confirmed to have plasma leak.

Table No 02: Laboratory parameters (n=40)

Laboratory values	No. of Patients	Percentage %
HCT >45% in males	4	10
HCT >40% in females	1	2.5
Leucopenia on admission	25	62.5
Leucopenia during hospital stay	34	85
Thrombocytopenia on admission	31	77.5
Thrombocytopenia during hospital stay	37	92.5
Serum bilirubin (>17 $\mu\text{mol/L}$)	1	2.5
ALT (>42 U/l)	12	30
Serum Urea (>7.1 mmol/l)	1	2.5
Serum Creatinine (>115 $\mu\text{mol/L}$)	3	7.5
Hyponatraemia (≤ 135 mmol/l)	3	7.5
Hypernatraemia (≥ 150 mmol/l)	1	2.5
Hyperkalemia (≥ 5.0 mmol/l)	3	7.5
DIC	1	2.5

One patient died in our study. This patient had DSS. All the rest 39 patients recovered uneventfully.

DISCUSSION:

Our study describes the demographic pattern, clinical features, investigations and outcome of dengue fever in patients admitted in Benazir Bhutto Hospital, Rawalpindi. Results of this study showed that patients admitted in Benazir Bhutto Hospital Rawalpindi had a milder presentation of disease. In our knowledge this was the first study in which clinical features and laboratory parameters were evaluated in the Rawalpindi region during the epidemic of 2018.

Our study showed male predominance among the patients. Most studies done In India, Pakistan, and Asia pacific region showed similar gender distribution [10-15]. The reasons for this could be that men are more likely to seek health care facilities; they dominate as workforce and are more exposed to mosquito bite because of work place environment. Another reason might be that women are less exposed to mosquito bite because of their clothing. However above quoted studies were hospital based, instead population based sero-epidemiologic studies are

required to find out exact gender distribution among the population.

In our study maximum cases of dengue fever were seen in the post monsoon month of October. This is in accordance with results of Rawalpindi based study by Zafar et al [16] However Almas et al reported peak incidence of dengue fever in rainy season [17]. The monsoon months in Rawalpindi are July and August, sometime stretched up to mid-September. We think that time lapse for peak incidence of dengue fever following monsoon can be due to time required by *Aedes* mosquitoes to breed in the pooled-up water.

Our study showed that 57.5% patients had chills and rigors. Chills and rigors were not reported in most of the studies; however, Ahmed et al and Khan et al reported these symptoms in 80% of cases [18,19]. In our study 20% patients had abdominal pain. Interestingly this was in sharp contrast to the results of most studies which reported this symptom in the range of 41- 65% [9,14,16,20]. Headache and myalgias were seen in 62.5% cases in our study. These symptoms were reported similarly by other studies [16,18,19,21]. Vomiting occurred in 35% of our patients, comparable to many studies [11,12,16,20], however other studies reported this symptom in 57.5%, 85%, 60%, and 77.5% cases; these figures are considerably higher than ours [10,14,19,22]. In our study 27% patients had pruritus while Daniel et al and Fujimoto et al reported this symptom in 10.4%, and 8.8% cases respectively [9,20]. Skin rash in our study was 20%, comparable to other studies [18,19,20]. However, Ahmed et al and Zafar et al documented this symptom in 56% and 41.3% cases respectively [14,16].

Retro-orbital pain was present in 42.5% of our patients. However, in literature the reported incidence of retro-orbital pain had wide variations. Kausar et al, Ahmed et al and Fujimoto et al reported this symptom in 12.3%, 20%, and 16.1% cases respectively [10,14,20]. However, Zafar et al reported this symptom in 65.3% [16]. Diarrhoea was reported in 10% of our cases. Similar figure has been reported by Daniel et al [9] however Zafar et al reported this symptom in 37.5% [16].

Reported incidence of bleeding manifestations had wide variations in literature. Vanamali et al and Fujimoto et al reported this feature in 32%, and 35% cases respectively [11,20]. In Rawalpindi population Zafar et al documented hematemesis in 28.8%, gum bleeding in 25%, melaena in 17.35, and hemoptysis in 12.5% cases [16]. However, we noticed bleeding in only 2.5% of our cases. In our study only one patient

had pleural effusion and ascites. In other studies, pleural effusion was found in 13.2% and 13.6% [9,10]. Daniel et al reported ascites in 12% of cases [9].

Thrombocytopenia and leucopenia were common findings in our study. Thrombocytopenia was seen in 92.5% and leucopenia in 85% cases. Other studies had similar pattern of cytopenia [12,14,18,19]. We found that leucopenia preceded development of thrombocytopenia. This is important as patients may present with leucopenia only. The analysis of liver functions in our study showed that bilirubin was raised in only 1 case while ALT was raised in 12 cases (30%). Other studies reported raised ALT in 80.8%, 62%, and 57% cases; these figures are higher than our study [12,14,18]. In our study only one patient had DIC highlighting the fact that patients in our series had a milder form of dengue fever.

The ratio of DF to DHF/DSS reported in literature had wide variation. In our series only one patient had DSS, comparable to other studies done in Pakistan [18,19,22]. However Riaz et al reported 39% cases of DHF/DSS in his study [23]. Wasay et al reported that combined cases of DHF and DSS rose from 12.5% in year 2000-2004 to 42% in year 2005 [24]. Daniel et al from India also reported 33.6% cases of DHF/DSS in his study [9].

Mortality in our study was 2.5%. Mortality reported in literature varied from 0.68% to 7.3% [13,20]. The difference in clinical features, laboratory parameters, and mortality in our study as compared to rest of the studies could be explained by the fact that only one out of 40 patients in our series had DSS and rest of the cases were of DF. The reason for low incidence of DHF/DSS in our setup in year 2018-19 could be that the dengue virus was of a less virulent serotype. The other reasons could be that the population under study was relatively healthy, had better access to health facilities and most importantly probably naïve to the dengue virus. It is expected that in future we may encounter epidemics with higher morbidity and mortality.

We decided to do hospital-based study with the view to better document and understand our patients but this was also the major limitation of our study. The other limitations of our study were that serotyping of dengue virus was not done and status of previous dengue exposure was not known. We suggest that sero-epidemiologic studies should be done in future to document previous exposure and to find out the serotype in upcoming epidemic. Moreover, studies on the clinical presentation of dengue fever should be

multicenter so that they can be better representative of dengue epidemics.

First DF vaccine, Dengvaxia (CYD-TDV) has been registered in Mexico in 2016 by WHO [25]. This is likely to change dengue fever landscape all over the world; in future studies will be required to investigate the changing pattern of dengue fever.

CONCLUSION:

This study showed that patients admitted to our hospital had a milder presentation of dengue fever in year 2018. This study further highlighted the temporal and regional variations in presentation and severity of dengue fever.

REFERENCES:

1. World Health Organization. Comprehensive guidelines for prevention and control of dengue and dengue hemorrhagic fever. Available from: http://apps.searo.who.int/pds_docs/B4751.pdf.
2. Guzman MG, Kouri G. Dengue: an update. *Lancet Infect Dis* 2001; 2: 33-42.
3. Akram DS, Igarshi A, Takayasu T. Dengue virus infection among children with undifferentiated fever in Karachi. *Ind J Paediatr* 1998; 65: 735-40.
4. Khan E, Siddique J, Shakoor S, Mehraj V, Jamil B, Hassan R. Dengue outbreak in Karachi Pakistan: experience at a tertiary care centre. *Trans R Soc Trop Med Hyg* 2007; 101: 114-9.
5. Idrees M, Hussain W, Rehman H, Tayyab G, Afzal S, Fatima Z, et al. Dengue Virus Serotype 2 (DEN-2): The Causative Agent of 2011-Dengue Epidemic in Pakistan. *Am J Biomed Sci* 2012; 4(4): 307-15.
6. Dash PK, Parida MM, Saxena P, Kumar M, Rai A, Pasha ST, et al. Emergence and continued circulation of Dengue-2 (genotype IV) virus strains in northern India. *J Med Virol* 2004; 74: 314-22.
7. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et.al. The global distribution and burden of dengue. *Nature* 2013; 496: 504-507.
8. Ministry of National Health Services. Seasonal awareness and alert letter for epidemic-prone infectious diseases in Pakistan. Available from: [http://nih.org.pk/files/newsletter/seasonal%20Awareness%20and%20Alert%20Letter%20\(SAAL\)%2034th%20Issue.pdf](http://nih.org.pk/files/newsletter/seasonal%20Awareness%20and%20Alert%20Letter%20(SAAL)%2034th%20Issue.pdf) (Accessed 2016).
9. Daniel R, Rajamohanam, Philip AZ. A study of clinical profile of dengue fever in kollam, kerala, India. *Dengue Bulletin* 2005; 29: 197-202.
10. Kauser MM, Kalavathi GP, Radadiya M, Karthik M, Afreen A, Kumaraswamy RC, et al. A study of clinical and laboratory profile of dengue fever in tertiary care hospital in central karnataka, india. *Global Journal of medical research* 2014; 14(5): 6-12.
11. Vanamali DR, Venugopal L, Yeshwanth P, Rampure D. A study on clinical, laboratory profile and outcome of dengue fever. *Journal of evolution of medical and dental sciences* 2013; 50(2): 9739-43.
12. Rehman M, Butt A, Shahzad M, Iqbal A, Semab. Dengue fever outbreak 2010: clinical experience in a teaching hospital of Lahore Pakistan. *Pak J Med Health Sci* 2011; 5(2): 256-59.
13. Qureshi JA, Notta NJ, Salahuddin N, Zaman V, Khan JA. An epidemic of dengue Fever in Karachi-associated clinical manifestations. *J Pak Med Assoc* 1997; 47(7): 178-81.
14. Ahmed SI, Khalid MA, Baqai HZ, Ali SF, Ranja ZA. Dengue fever in Northern Pakistan: the hepatic implications. *J Rawal Med Coll* 2009; 13(2): 56-59.
15. Anker M, Arima Y. Male-female differences in the number of reported incident dengue fever cases in six Asian countries. *Western Pacific Surveillance and Response Journal* 2011; 2(2): 17-23.
16. Zafar H, Hayyat J, Bukhari KT, Awan ZI, Ahmed I, Asad M. Regional variation and clinical manifestations of acute dengue infection observed at a tertiary care hospital of district Rawalpindi. *Isra Med J* 2014; 6(2): 70-74.
17. Almas A, Parkash O, Akhter J. Clinical factors associated with mortality in dengue infection at a tertiary care center. *Southeast Asian J Trop Med Public Health* 2010; 41(2): 333-40.
18. Ahmed S, Ali N, Ashraf S, Ilyas M, Tariq WU, Chotani RA. Dengue fever outbreak: a clinical management experience, *J Coll Physicians Surg Pak* 2008; 18 (1): 8-12.
19. Khan AH, Hayat AS, Masood N, Solangi NM, Shaikh TZ. Frequency and clinical presentation of dengue fever at tertiary care hospital of Hyderabad/Jamshoro. *J Liaquat Uni Med Health Sci* 2010; 9(2): 88-94.
20. Fujimoto DE, Koifman S. Clinical and laboratory characteristics of patients with dengue hemorrhagic fever manifestations and their transfusion profile. *Rev Bras hematol Hemoter* 2014; 36(2): 115-20.
21. Khan HMS, Zaman Q, Khan BA, Arif M, Raza A, Haq A. Retrospective analysis of 68 cases of dengue fever. *Pak J Med Res* 2012; 51(1): 18-20.
22. Ansari JK, Siddiq M, Hussain T, Baig I, Tariq WZ. Outbreak of dengue hemorrhagic fever in

- Karachi. Pak Armed Forces Med J 2001; 51(2): 94-8.
23. Riaz M, Mumtaz K, Khan M, Patel J, Tariq M, Hilal H et al. Outbreak of dengue fever in Karachi 2006: a clinical perspective. J Pak Med Asso 2009; 59(6): 339-44.
 24. Wasay M, Channa R, Jumani M, Zafar A. Changing patterns and outcome of dengue infection; report from tertiary hospital in Pakistan. J Pak Med Assoc 2008; 58(9): 488-9.
 25. World Health Organization. Immunization, vaccines and biological. [http:// www.who.int/immunization/ research/ development/dengue_vaccines/en/](http://www.who.int/immunization/research/development/dengue_vaccines/en/) (Accessed on 2016).